Porton Pharma Solutions Ltd. (300363.SZ)
CNY 17.08
(0.59%)
CNY 17.08
(0.59%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.38 Billion CNY | -7.49% |
| 2022 | 10.14 Billion CNY | 54.59% |
| 2021 | 6.56 Billion CNY | 45.92% |
| 2020 | 4.49 Billion CNY | 13.69% |
| 2019 | 3.95 Billion CNY | -9.58% |
| 2018 | 4.37 Billion CNY | 53.59% |
| 2017 | 2.84 Billion CNY | -0.81% |
| 2016 | 2.87 Billion CNY | 20.68% |
| 2015 | 2.37 Billion CNY | 28.27% |
| 2014 | 1.85 Billion CNY | 95.65% |
| 2013 | 948.09 Million CNY | 19.85% |
| 2012 | 791.08 Million CNY | 37.74% |
| 2011 | 574.31 Million CNY | 24.74% |
| 2010 | 460.41 Million CNY | 51.18% |
| 2009 | 304.54 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 8.87 Billion CNY | -3.66% |
| 2024 Q1 | 9.21 Billion CNY | -1.83% |
| 2024 Q3 | 8.92 Billion CNY | 0.52% |
| 2023 Q4 | 9.38 Billion CNY | 3.24% |
| 2023 FY | 9.38 Billion CNY | -7.49% |
| 2023 Q3 | 9.08 Billion CNY | -4.36% |
| 2023 Q2 | 9.5 Billion CNY | -5.19% |
| 2023 Q1 | 10.02 Billion CNY | -1.19% |
| 2022 Q2 | 9.54 Billion CNY | 25.98% |
| 2022 Q1 | 7.57 Billion CNY | 15.44% |
| 2022 FY | 10.14 Billion CNY | 54.59% |
| 2022 Q4 | 10.14 Billion CNY | -0.03% |
| 2022 Q3 | 10.14 Billion CNY | 6.33% |
| 2021 Q3 | 5.87 Billion CNY | 12.1% |
| 2021 Q1 | 4.68 Billion CNY | 4.16% |
| 2021 FY | 6.56 Billion CNY | 45.92% |
| 2021 Q4 | 6.56 Billion CNY | 11.68% |
| 2021 Q2 | 5.24 Billion CNY | 11.9% |
| 2020 Q2 | 4.16 Billion CNY | 3.23% |
| 2020 FY | 4.49 Billion CNY | 13.69% |
| 2020 Q4 | 4.49 Billion CNY | 2.0% |
| 2020 Q3 | 4.4 Billion CNY | 5.95% |
| 2020 Q1 | 4.03 Billion CNY | 1.91% |
| 2019 Q1 | 4.24 Billion CNY | -2.92% |
| 2019 Q3 | 4.04 Billion CNY | -1.38% |
| 2019 FY | 3.95 Billion CNY | -9.58% |
| 2019 Q4 | 3.95 Billion CNY | -2.3% |
| 2019 Q2 | 4.1 Billion CNY | -3.33% |
| 2018 Q4 | 4.37 Billion CNY | -0.27% |
| 2018 Q3 | 4.38 Billion CNY | -5.4% |
| 2018 Q2 | 4.63 Billion CNY | 67.13% |
| 2018 Q1 | 2.77 Billion CNY | -2.59% |
| 2018 FY | 4.37 Billion CNY | 53.59% |
| 2017 Q2 | 2.71 Billion CNY | -10.04% |
| 2017 Q1 | 3.01 Billion CNY | 5.03% |
| 2017 FY | 2.84 Billion CNY | -0.81% |
| 2017 Q4 | 2.84 Billion CNY | 7.62% |
| 2017 Q3 | 2.64 Billion CNY | -2.46% |
| 2016 Q1 | 2.43 Billion CNY | 2.17% |
| 2016 Q2 | 2.66 Billion CNY | 9.45% |
| 2016 Q3 | 2.63 Billion CNY | -1.01% |
| 2016 FY | 2.87 Billion CNY | 20.68% |
| 2016 Q4 | 2.87 Billion CNY | 9.02% |
| 2015 FY | 2.37 Billion CNY | 28.27% |
| 2015 Q4 | 2.37 Billion CNY | 4.08% |
| 2015 Q3 | 2.28 Billion CNY | 21.88% |
| 2015 Q2 | 1.87 Billion CNY | 4.28% |
| 2015 Q1 | 1.79 Billion CNY | -3.03% |
| 2014 Q4 | 1.85 Billion CNY | 18.64% |
| 2014 Q3 | 1.56 Billion CNY | 3.65% |
| 2014 FY | 1.85 Billion CNY | 95.65% |
| 2014 Q2 | 1.5 Billion CNY | 20.73% |
| 2014 Q1 | 1.24 Billion CNY | 31.77% |
| 2013 FY | 948.09 Million CNY | 19.85% |
| 2013 Q4 | 948.09 Million CNY | 0.0% |
| 2013 Q2 | 788.14 Million CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2012 FY | 791.08 Million CNY | 37.74% |
| 2011 FY | 574.31 Million CNY | 24.74% |
| 2010 FY | 460.41 Million CNY | 51.18% |
| 2009 FY | 304.54 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Beijing Scitop Bio-tech Co., Ltd. | 1.81 Billion CNY | -418.426% |
| Lifecome Biochemistry Co.,Ltd. | 1.96 Billion CNY | -377.556% |
| Chengdu Kanghua Biological Products Co., Ltd. | 4.2 Billion CNY | -122.937% |
| NanHua Bio-medicine Co., Ltd | 771.38 Million CNY | -1116.521% |
| Shandong Sito Bio-technology Co., Ltd. | 3.24 Billion CNY | -189.609% |
| Zhejiang Wecome Pharmaceutical Company Limited | 2.04 Billion CNY | -358.51% |
| Guangdong VTR Bio-Tech Co., Ltd. | 3.09 Billion CNY | -203.206% |